Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference
Ventyx Biosciences (Nasdaq: VTYX) announced that CEO Raju Mohan will present a company overview at the Barclays Global Healthcare Conference on March 16, 2022, from 2:35-3:00 PM ET in Miami, Florida.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ventyx Biosciences (Nasdaq: VTYX) announced that CEO Raju Mohan will present a company overview at the Barclays Global Healthcare Conference on March 16, 2022, from 2:35-3:00 PM ET in Miami, Florida. The management team will also hold investor meetings during the event. Ventyx focuses on developing therapies for inflammatory diseases and autoimmune disorders, with a portfolio that includes VTX958, VTX002, and VTX2735, targeting various conditions. A webcast of the presentation will be available on their website for 30 days post-event.
Details
News Market Reaction – VTYX
The recorded move for VTYX in the trading session of this news was -2.81%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the Barclays Global Healthcare Conference being held March 15-17, 2022.
- Event: Barclays Global Healthcare Conference
Location: Miami, Florida
Date: Wednesday, March 16, 2022
Time: 2:35-3:00 PM ET
Members of the Ventyx management team will also host investor meetings during the conference.
A webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for 30 days.
About Ventyx
Ventyx is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Our clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2 S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit: www.ventyxbio.com.
Investor Relations Contact:
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.